Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peng-Peng Xu

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Signal Transduction and Targeted Therapy|October 5, 2023
Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphomaYing Fang, Mu-Chen Zhang, Yang He, et al.
Autophagy|January 7, 2016
Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activationMeng-Meng Ji, Li Wang, Qin Zhan, et al.
Annals of Translational Medicine|November 18, 2021
Development and validation of prognostic scoring in primary intestinal diffuse large B-cell lymphoma: a single-institution study of 184 patientsXing Fan, Lu Zang, Bing-Bing Zhao, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2022
The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature ReviewPeng-Peng Xu, Rong Shen, Zi-Yang Shi, et al.
Clinical Epigenetics|October 24, 2020
Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphomaMu-Chen Zhang, Ying Fang, Li Wang, et al.
Clinical and Translational Medicine|November 30, 2020
Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphomaRong Shen, Peng-Peng Xu, Nan Wang, et al.
Ebiomedicine|February 4, 2017
B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort StudyPeng-Peng Xu, Hui-Juan Zhong, Yao-Hui Huang, et al.
Practical Radiation Oncology|July 6, 2026
Locoregional recurrence patterns and prognostic outcomes in early-stage natural killer/T-cell lymphoma treated with sandwich chemoradiotherapy: A post hoc analysis of a randomized controlled trialShu-Bei Wang, Jia-Yi Chen, Qi Song, et al.
Cell Death & Disease|March 26, 2021
A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexesPing Zhao, Meng-Meng Ji, Ying Fang, et al.
Nature Communications|June 18, 2024
Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphomaZi-Xun Yan, Yan Dong, Niu Qiao, et al.
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Signal Transduction and Targeted Therapy|October 5, 2023
Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphomaYing Fang, Mu-Chen Zhang, Yang He, et al.
Autophagy|January 7, 2016
Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activationMeng-Meng Ji, Li Wang, Qin Zhan, et al.
Annals of Translational Medicine|November 18, 2021
Development and validation of prognostic scoring in primary intestinal diffuse large B-cell lymphoma: a single-institution study of 184 patientsXing Fan, Lu Zang, Bing-Bing Zhao, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2022
The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature ReviewPeng-Peng Xu, Rong Shen, Zi-Yang Shi, et al.
Clinical Epigenetics|October 24, 2020
Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphomaMu-Chen Zhang, Ying Fang, Li Wang, et al.
Clinical and Translational Medicine|November 30, 2020
Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphomaRong Shen, Peng-Peng Xu, Nan Wang, et al.
Ebiomedicine|February 4, 2017
B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort StudyPeng-Peng Xu, Hui-Juan Zhong, Yao-Hui Huang, et al.
Practical Radiation Oncology|July 6, 2026
Locoregional recurrence patterns and prognostic outcomes in early-stage natural killer/T-cell lymphoma treated with sandwich chemoradiotherapy: A post hoc analysis of a randomized controlled trialShu-Bei Wang, Jia-Yi Chen, Qi Song, et al.
Cell Death & Disease|March 26, 2021
A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexesPing Zhao, Meng-Meng Ji, Ying Fang, et al.
Nature Communications|June 18, 2024
Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphomaZi-Xun Yan, Yan Dong, Niu Qiao, et al.
Pageof 9